Ankur Shah, MD
Retina Specialist · Carmel, INNPI 1851590343
Payments from drug & device makers
Across 630 payments — averaging $3241.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$975K
- Novartis$269K
- Regeneron Healthcare Solutions, Inc.$264K
- Regeneron$237K
- Apellis Pharmaceuticals, Inc.$218K
- Astellas Pharma US Inc$28K
- plus $51K from 19 others
What the payments were for
- Consulting fees$43,6348%
- Speaking & faculty fees$421,85174%
- Travel & lodging$84,21715%
- Food & beverage$19,5223%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 60 | $974,792 |
| Novartis | 17 | $269,127 |
| Regeneron Healthcare Solutions, Inc. | 192 | $264,118 |
| Regeneron | 17 | $236,964 |
| Apellis Pharmaceuticals, Inc. | 141 | $218,267 |
| Astellas Pharma US Inc | 32 | $27,808 |
| Alimera Sciences, Inc. | 38 | $15,965 |
| Genentech USA, Inc. | 42 | $11,148 |
| AbbVie(2 entities) | 44 | $10,664 |
| Eyepoint US, Inc. | 16 | $9,348 |
| Ocular Therapeutix, Inc. | 3 | $2,564 |
| Alcon Research LLC | 1 | $350 |
| Biogen | 7 | $279 |
| Amgen(2 entities) | 3 | $190 |
| Harrow Eye, LLC | 3 | $165 |
| Cardinal Health 110 LLC | 1 | $150 |
| Astellas Pharma Global Development | 1 | $133 |
| Spark Therapeutics, Inc. | 1 | $111 |
| ANI Pharmaceuticals, Inc. | 3 | $62 |
| Bausch & Lomb Americas Inc. | 3 | $61 |
| Neurotech Pharmaceuticals, Inc. | 1 | $30 |
| Alcon | 1 | $22 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $16 |
| Merck | 1 | $16 |
| Dexcel Pharma Technologies Ltd. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,042,364 in reported general payments places this provider in the 95th percentile of 21 retina specialist providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 25 | $2,896 |
| Prednisolone Acetate | 32 | $923 |
| Timolol Maleate | 17 | $406 |
| Brimonidine Tartrate | 40 | $285 |
| Dorzolamide Hcl | 12 | $240 |
| Latanoprost | 15 | $196 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Carmel
- Raj MaturiCarmel$3.3M
- Milan ShahCarmel$802K
- Ramana MoorthyCarmel$378K
- Rodney BucherCarmel$30K
- Stephen SaxeCarmel$14K
- Denis JusufbegovicCarmel$8K
- Mark KaehrCarmel$5K
- Julia HudsonCarmel$3K
- Frederick PrallCarmel$475
- John MinturnCarmel$133
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.